Printer Friendly

DURA PHARMACEUTICALS PROVIDES ADDITIONAL INFORMATION ON DEVELOPMENT OF DRYHALER DRUG DELIVERY SYSTEM

 SAN DIEGO, Oct. 25 /PRNewswire/ -- Dura Pharmaceuticals Inc. (NASDAQ: DURA) indicated today at an investment conference that it expects to conduct clinical trials in 1994 and 1995 on behalf of Dura Delivery Systems Inc. (DDSI) using the Dryhaler, a proprietary dry powder inhaler drug delivery system, with formulations of three currently marketed asthma drugs -- ipratropium, bitolterol and albuterol. The company also indicated that it expects to submit NDAs on behalf of DDSI for the use of the Dryhaler with those formulations by the end of 1995, with potential approval by the Food and Drug Administration (FDA) projected by 1996 or 1997.
 Dura had announced recently that the company and DDSI, a newly formed Delaware corporation, completed a $13 million private placement to fund development of the Dryhaler initially with formulations of these three drugs. DDSI may also develop and market in the Dryhaler five additional drugs -- triamcinolone, becolmethasone, cromolyn, flunisolide and budesonide -- by seeking financing arrangements with various corporate partners.
 At the conference, Dura indicated that the potential market for dry powder formulations of these eight respiratory drugs could exceed $1 billion by the year 2002.
 In addition to its use with these respiratory pharmaceuticals, Dura's Dryhaler may also be licensed to pharmaceutical companies in the future for use with novel, late-stage respiratory drugs, and may also be used with non-respiratory products, including proteins and peptides, which are being developed by biotechnology companies.
 Dura estimated that the potential market for the dry powder formulations of novel respiratory products could exceed $2 billion and that the potential market for dry powder formulations of non-respiratory drugs could exceed $3 billion by the year 2002.
 Dura's Dryhaler offers several advantages over existing inhalation delivery systems, including the lack of chlorofluorocarbon propellants, and is designed to deliver a relatively consistent dose to the lungs independent of the patient's ability to inhale.
 There can be no assurance that the clinical trials or Dura's efforts to obtain FDA approval of the products will be successful.
 Dura Pharmaceuticals Inc. is a San Diego-based developer and marketer of prescription pharmaceutical products, drug delivery systems and medical devices for the treatment of allergies, asthma and related respiratory conditions.
 -0- 10/25/93
 /CONTACT: James W. Newman, VP, Finance and Administration, 619-457-2553/
 (DURA)


CO: Dura Pharmaceuticals Inc. ST: California IN: MTC SU:

EH -- SD005 -- 6202 10/25/93 10:17 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 25, 1993
Words:391
Previous Article:HUMPHREY INC. SIGNS MERGER AGREEMENTWITH REMEC INC., 3RD QTR EARNINGS REPORTED
Next Article:CARAUSTAR INDUSTRIES REPORTS THIRD QUARTER, NINE-MONTH RESULTS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters